<DOC>
	<DOCNO>NCT03104595</DOCNO>
	<brief_summary>This study ass treatment febrile neutropenia subject relapse metastatic breast cancer whose risk level febrile neutropenia low receive second line high chemotherapy incorporates doxorubicin/cyclophosphamide .</brief_summary>
	<brief_title>Management Severe Chemotherapy-induced Neutropenia Advanced Breast Cancer</brief_title>
	<detailed_description>This study ass treatment febrile neutropenia subject relapse metastatic breast cancer enrol total 12 subject initially receive 1 4 dose level EC-18 ( 3 subject per dose level ) . Subjects evaluate dose-limiting side effect occur dose level . EC-18 administration discontinue 3-week treatment period . EC-18 treatment administer continuously 21 day coincide cycle chemotherapy . The risk infection base absolute neutrophil count assess period . After 21 day EC-18 treatment , subject follow 4-week safety assessment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>1 . Women ≥19 year age 2 . Subjects voluntarily sign informed consent prior screen test participate study 3 . Subjects diagnose adenocarcinoma breast relapse adjuvant primary ( neoadjuvant ) chemotherapy , thus history confirm candidate chemotherapy second line high ( include hormonal therapy ) combine doxorubicin cyclophosphamide treat relapse metastatic disease . 4 . Subjects adequate organ function base follow clinical laboratory value final examination perform within 14 day prior dose : Neutrophil count ( ANC ) : ≥1,500/mm3 Platelet count : ≥10.0×104/mm3 Hemoglobin : ≥9.0 g/dL AST , ALT : ≤100 IU/L Serum total bilirubin : ≤1.5 mg/dL • Serum creatinine : ≤1.5 mg/dL 5 . Subjects whose Eastern Cooperative Oncology Group ( ECOG ) performance score 01 . 6 . For woman child bear potential , subject willingness use acceptable contraceptive method entire clinical study period . 7 . Subjects capable understand overall procedure clinical trial willing participate compliance test procedure . 1 . Subjects active inactive hepatitis , patient HIV , uncontrolled infectious disease . 2 . Subjects currently undergoing/receiving antiretroviral therapy due previous current immunosuppressive virus infection , hepatitis B surface antigen positive , positive hepatitis C disease . 3 . Subjects receive radiation therapy within 4 week dose . 4 . Subjects diagnose within 5 year type cancer except appropriately treat superficial nonmelanoma skin cancer cervical intraepithelial neoplasia . 5 . Subjects history intolerance granulocyte colony stimulate factor treatment 6 . Subjects expect show hypersensitivity study drug ingredient 7 . Subjects positive urine pregnancy test result prior screen visit first administration study drug 8 . Subjects take study drug use clinical trial within 30 day prior screen visit . 9 . Clinically significant unstable medical abnormality ; psychiatric disorder , chronic disease , alcohol drug use disorder , significant biological , psychological , social factor , investigator 's opinion , unfavorably affect riskbenefit ratio study participation likely interfere satisfactory study completion confound outcome . 10 . Subjects unstable heart disease ( Example : Congestive heart failure , arrhythmia , symptomatic coronary artery disease ) ; Myocardial infarction within 6 month initiation study . 11 . Subjects leave ventricular ejection fraction ( LVEF ) &lt; 50 % screening . 12 . Significant neurological psychiatric disorder include dementia seizure . 13 . Subjects poorly control hypertriglyceridemia ( &gt; 500mg/dL ) use hypolipidemic agent . 14 . Subjects poorly control diabetes ( fast glucose &gt; 150 mg / dL HbA1c ≥ 8 % ) . 15 . Subjects receive systemic chemotherapy doxorubicin anticancer agent treat metastatic recurrent breast cancer 16 . Subjects Grade 2 high peripheral sensory neuropathy prior screen visit first dose study drug 17 . Subjects undergone significant gastrectomy intractable nausea vomiting , chronic gastrointestinal disease , clinically significant sequela , would interfere proper absorption study drug 18 . Subjects administer systemic antibiotic within 14 day prior administration study drug 19 . Subjects whose cumulative dose doxorubicin exceed 240 mg/m2 ' 20 . Subjects currently receive trastuzumab</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EC-18 , febrile neutropenia , breast cancer , chemotherapy</keyword>
</DOC>